According to a recent LinkedIn post from Vektor Medical Inc, the company has been selected to participate in MedTech Innovator’s Radar Forum. The post notes that Vektor is among more than 140 ventures that passed the program’s initial diligence filters to pitch before a large audience of judges, investors, strategic partners, and clinicians.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights that CEO Rob Krummen is scheduled to present Vektor’s story and discuss how its vMap technology is affecting electrophysiology (EP) labs and patient outcomes. For investors, participation in MedTech Innovator’s forum may signal growing industry validation, potential access to new strategic relationships, and expanded visibility that could support future fundraising or commercial partnerships in the medtech and cardiac mapping segments.